Reilly Financial Advisors adds Pfizer (PFE) to its portfolio

Pfizer (PFE) : Reilly Financial Advisors added new position in Pfizer during the most recent quarter end. The investment management firm now holds 301,159 shares of Pfizer which is valued at $10,627,901 , the company said in a statement filed on Aug 3, 2016 with the SEC.Pfizer makes up approximately 1.90% of Reilly Financial Advisors’s portfolio.

Other Hedge Funds, Including , Swiss National Bank boosted its stake in PFE in the latest quarter, The investment management firm added 1,412,800 additional shares and now holds a total of 18,298,389 shares of Pfizer which is valued at $645,750,148. Pfizer makes up approx 1.02% of Swiss National Bank’s portfolio.Oxbow Advisors reduced its stake in PFE by selling 29,510 shares or 7.38% in the most recent quarter. The Hedge Fund company now holds 370,305 shares of PFE which is valued at $13,068,063. Pfizer makes up approx 1.83% of Oxbow Advisors’s portfolio.Wheatland Advisors Inc reduced its stake in PFE by selling 500 shares or 1.14% in the most recent quarter. The Hedge Fund company now holds 43,331 shares of PFE which is valued at $1,529,151. Pfizer makes up approx 0.80% of Wheatland Advisors Inc’s portfolio.Dorchester Wealth Management Co reduced its stake in PFE by selling 41,329 shares or 25.37% in the most recent quarter. The Hedge Fund company now holds 121,554 shares of PFE which is valued at $4,465,894. Pfizer makes up approx 1.62% of Dorchester Wealth Management Co’s portfolio.V Wealth Managementllc reduced its stake in PFE by selling 265 shares or 2.92% in the most recent quarter. The Hedge Fund company now holds 8,814 shares of PFE which is valued at $323,298. Pfizer makes up approx 0.26% of V Wealth Managementllc’s portfolio.

Pfizer closed down -0.51 points or -1.44% at $34.93 with 3,05,40,494 shares getting traded on Monday. Post opening the session at $35.28, the shares hit an intraday low of $34.71 and an intraday high of $35.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.